MX386256B - Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. - Google Patents

Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.

Info

Publication number
MX386256B
MX386256B MX2018003569A MX2018003569A MX386256B MX 386256 B MX386256 B MX 386256B MX 2018003569 A MX2018003569 A MX 2018003569A MX 2018003569 A MX2018003569 A MX 2018003569A MX 386256 B MX386256 B MX 386256B
Authority
MX
Mexico
Prior art keywords
acid derivatives
oleanolic acid
inhibition
modified
formula
Prior art date
Application number
MX2018003569A
Other languages
English (en)
Spanish (es)
Other versions
MX2018003569A (es
Inventor
Bradley William Caprathe
Gary Bolton
Xin Jiang
Chitase Lee
Martha R Hotema
Melean Visnick
William H Roark
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of MX2018003569A publication Critical patent/MX2018003569A/es
Publication of MX386256B publication Critical patent/MX386256B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2018003569A 2015-09-23 2016-09-23 Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. MX386256B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222632P 2015-09-23 2015-09-23
PCT/US2016/053545 WO2017053868A1 (en) 2015-09-23 2016-09-23 C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses

Publications (2)

Publication Number Publication Date
MX2018003569A MX2018003569A (es) 2018-11-29
MX386256B true MX386256B (es) 2025-03-18

Family

ID=57137257

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003569A MX386256B (es) 2015-09-23 2016-09-23 Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.

Country Status (14)

Country Link
US (2) US11584775B2 (https=)
EP (1) EP3353190B1 (https=)
JP (1) JP7074674B2 (https=)
KR (1) KR102796889B1 (https=)
CN (1) CN108290922B (https=)
AU (1) AU2016326704B2 (https=)
BR (1) BR112018005861B1 (https=)
CA (1) CA2998681C (https=)
EA (1) EA201890767A1 (https=)
ES (1) ES2865163T3 (https=)
IL (1) IL258185B (https=)
MX (1) MX386256B (https=)
NZ (1) NZ741082A (https=)
WO (1) WO2017053868A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター:c−17においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
TWI623548B (zh) 2012-04-27 2018-05-11 瑞塔醫藥有限責任公司 齊墩果酸(bardoxolone methyl)之2,2-二氟基丙醯胺衍生物、多晶型及其使用方法
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
JP6243428B2 (ja) 2012-09-10 2017-12-06 リアタ ファーマシューティカルズ インコーポレイテッド オレアノール酸のc17−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法
AR096046A1 (es) 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
JP7074674B2 (ja) 2015-09-23 2022-05-24 リアタ ファーマシューティカルズ インコーポレイテッド Il-17の阻害及び他の使用のためのc4修飾オレアノール酸誘導体
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
CN108299541B (zh) * 2018-01-18 2020-12-11 华南师范大学 海洋微生物来源的二倍半萜AsperterpinolB衍生物及合成方法与抗炎应用
CN108191944B (zh) * 2018-01-18 2020-12-11 华南师范大学 海洋微生物来源的二倍半萜AsperterpinolB衍生物及合成方法与糖酶应用
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
CN109248168A (zh) * 2018-10-30 2019-01-22 武汉卫无忧生物科技有限公司 齐墩果酸在制备抗幽门螺杆菌的药物中的用途
TWI752400B (zh) 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
EP3999522B1 (en) * 2019-07-19 2025-09-03 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
MX2023008454A (es) * 2021-01-18 2023-08-07 Reata Pharmaceuticals Inc Derivados sintéticos de ácido ursólico y métodos de uso de estos.
CN113185570A (zh) * 2021-05-12 2021-07-30 张洪胜 一种治疗银屑病的齐墩果酸衍生物及其制备方法
CN117964678A (zh) * 2024-01-29 2024-05-03 烟台大学 C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
DE19817262A1 (de) 1998-04-18 1999-10-21 Bayer Ag Neue 2-heterocyclisch substituierte Dihydropyrimidine
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
DE60043400D1 (de) 1999-05-14 2010-01-07 Nereus Pharmaceuticals Inc Interleukin-1 und Tumornekrosefaktor-alpha Modulatoren,Synthese dieser Modulatoren und Methoden zur Anwendung dieser Modulatoren
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
US6689767B2 (en) 2000-09-29 2004-02-10 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
AU2001294953A1 (en) 2000-09-29 2002-04-08 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
WO2002047611A2 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
AU2002308701A1 (en) 2001-05-14 2002-11-25 University Of Maryland, Baltimore Novel alanine transaminase enzyme and methods of use
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
CA2473799A1 (en) 2002-01-18 2003-07-31 Regents Of The University Of Minnesota Triterpene quaternary salts as biologically active surfactants
JP2006515859A (ja) 2002-05-13 2006-06-08 トラスティーズ オブ ダートマス カレッジ 阻害剤およびその使用法
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US20050208151A1 (en) 2003-10-30 2005-09-22 Entelos, Inc. Treatment of rheumatoid arthritis with FLIP antagonists
US8288439B2 (en) 2003-11-04 2012-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the inhibition of HIV-1 replication
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
JP2005314381A (ja) 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
JP5087400B2 (ja) 2004-09-07 2012-12-05 パシフィック アロー リミテッド アンゲロイル基を有する抗腫瘍化合物
AU2006265113A1 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20070232577A1 (en) 2006-03-23 2007-10-04 Advanced Life Sciences, Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
US20070249561A1 (en) 2006-04-25 2007-10-25 Taylor Bradley K Pharmacological method for treatment of neuropathic pain
WO2008000068A1 (en) 2006-06-27 2008-01-03 Wellington Laboratories Inc. Method for preparing 2-iodo triterpenoid compounds
WO2008016095A1 (en) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
EP2094651A1 (en) 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
EP2680010A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
WO2008111497A1 (ja) 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
WO2009023845A2 (en) 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
WO2009058849A1 (en) 2007-10-29 2009-05-07 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
BRPI0907423A2 (pt) 2008-01-11 2020-10-27 Reata Pharmaceuticals, Inc. composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター:c−17においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. C-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CN101298466B (zh) 2008-06-13 2014-04-09 南京大学 齐墩果酸衍生物及其制备方法和应用
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
SI2395979T1 (sl) 2009-02-13 2017-12-29 Reata Pharmaceuticals, Inc. Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem
DK2558105T3 (da) 2010-04-12 2020-01-27 Reata Pharmaceuticals Inc Bardoxolonmethyl til behandling af fedme
US8618125B2 (en) * 2011-01-14 2013-12-31 Heptiva LLC Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance
US8846647B2 (en) 2011-01-31 2014-09-30 Bristol-Myers Squibb Company C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity
MX348862B (es) * 2011-03-11 2017-07-03 Reata Pharmaceuticals Inc Derivados c4-monometil triterpenoides y sus metodos de uso.
CN103946231B (zh) 2011-12-01 2016-10-26 杭州本生药业有限公司 齐墩果酸酰胺化衍生物、及其制备方法和应用
TWI623548B (zh) 2012-04-27 2018-05-11 瑞塔醫藥有限責任公司 齊墩果酸(bardoxolone methyl)之2,2-二氟基丙醯胺衍生物、多晶型及其使用方法
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013169740A2 (en) 2012-05-08 2013-11-14 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
WO2013188818A1 (en) * 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
CN103665087A (zh) 2012-09-03 2014-03-26 上海源力生物技术有限公司 一种萜类化合物及其在医药上的应用
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
SMT201700501T1 (it) 2012-09-10 2017-11-15 Reata Pharmaceuticals Inc Derivati c17-eteroarilici dell'acido oleanolico e metodi d'uso degli stessi
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
JP6243428B2 (ja) 2012-09-10 2017-12-06 リアタ ファーマシューティカルズ インコーポレイテッド オレアノール酸のc17−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法
EP4736949A2 (en) 2013-08-23 2026-05-06 Reata Pharmaceuticals Holdings, LLC Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
CN104861027A (zh) 2014-02-24 2015-08-26 上海兰蒂斯生物医药科技有限公司 新型齐墩果酸衍生物、其制备方法及其应用
WO2016033132A1 (en) 2014-08-26 2016-03-03 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
JP7074674B2 (ja) 2015-09-23 2022-05-24 リアタ ファーマシューティカルズ インコーポレイテッド Il-17の阻害及び他の使用のためのc4修飾オレアノール酸誘導体
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
EP3999522B1 (en) 2019-07-19 2025-09-03 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
CA3159778A1 (en) 2019-12-19 2021-06-24 Reata Pharmaceuticals, Inc. Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof

Also Published As

Publication number Publication date
KR20180061251A (ko) 2018-06-07
WO2017053868A8 (en) 2018-04-19
IL258185A (en) 2018-05-31
BR112018005861B1 (pt) 2022-11-22
US11584775B2 (en) 2023-02-21
BR112018005861A2 (pt) 2018-10-16
EA201890767A1 (ru) 2019-09-30
CA2998681A1 (en) 2017-03-30
AU2016326704A1 (en) 2018-04-26
IL258185B (en) 2021-08-31
JP7074674B2 (ja) 2022-05-24
MX2018003569A (es) 2018-11-29
EP3353190A1 (en) 2018-08-01
ES2865163T3 (es) 2021-10-15
CN108290922B (zh) 2021-12-07
AU2016326704B2 (en) 2021-01-28
EP3353190B1 (en) 2021-03-17
NZ741082A (en) 2023-06-30
WO2017053868A1 (en) 2017-03-30
JP2018528275A (ja) 2018-09-27
HK1258095A1 (zh) 2019-11-01
US20230250130A1 (en) 2023-08-10
US12545701B2 (en) 2026-02-10
CN108290922A (zh) 2018-07-17
CA2998681C (en) 2024-02-06
US20190153022A1 (en) 2019-05-23
KR102796889B1 (ko) 2025-04-17

Similar Documents

Publication Publication Date Title
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
SA518391624B1 (ar) Ror- منظمات جاما
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
MX377845B (es) Inhibidores de calicreína plasmática humana.
MX375674B (es) Compuestos de carboxamida inhibidores de la actividad de cinasa rip2.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX394266B (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
CY1119615T1 (el) Διπλα εκλεκτικοι αναστολεις ρι3 δελτα και γαμμα κινασης
WO2015101957A3 (en) Inhibitors of glutaminase
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
MX382175B (es) Composiciones de profármaco de monometilfumarato
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
MX377919B (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
MX376090B (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas.
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.